The CDSCO Approval Process for Eye Drops in India: A Step-by-Step Guide

Every eye drop sold legally in India — from a simple lubricant to a fixed-dose glaucoma combination — has passed through a regulatory pathway defined by the Drugs and Cosmetics Act, 1940 and administered by the Central Drugs Standard Control Organization (CDSCO), working alongside State Drugs Control Departments. For distributors, hospital buyers and even prescribing ophthalmologists, understanding this pathway is useful for two reasons: it explains why some products take years to reach the market, and it tells you what documentation a legitimate manufacturer must hold.

This guide walks through the approval process for ophthalmic products step by step, based on the Drugs and Cosmetics Rules, 1945, the New Drugs and Clinical Trials (NDCT) Rules, 2019, and CDSCO's published procedures.

The Legal Foundation

India's drug regulation rests on three pillars:

• The Drugs and Cosmetics Act, 1940 — the parent legislation controlling the import, manufacture, distribution and sale of drugs.
• The Drugs and Cosmetics Rules, 1945 — the operational rules, including licensing forms, Schedules and specific provisions (Rules 122A, 122B, 122D, 122DA) governing new drug approval.
• The New Drugs and Clinical Trials Rules, 2019 — a major overhaul that replaced much of the older Schedule Y framework and now governs clinical trials, ethics committees, new drug approvals and accelerated pathways.

The apex regulator is CDSCO, headed by the Drugs Controller General of India (DCGI) under the Ministry of Health and Family Welfare. A crucial structural point: responsibility is split between the centre and the states. CDSCO approves new drugs, clinical trials, imports and fixed-dose combinations (FDCs); State Drugs Control Authorities issue manufacturing and sale licences for products already approved for marketing.

Step 1: Classify the Product

The first regulatory question is what kind of product the eye drop is:

Classification determines everything downstream — whether clinical trial data is needed, which form is filed, and which authority signs the licence.

Step 2: New Drug Approval via Form 44 (When Required)

If the product is a new drug, SND or FDC, the manufacturer applies to CDSCO using Form 44, supported by data in the Common Technical Document (CTD) format. The dossier covers:

• Module 1 — administrative information and Indian-specific documents
• Module 2 — summaries of quality, non-clinical and clinical data
• Module 3 — quality (CMC): formulation, manufacturing process, specifications, stability data
• Module 4 — non-clinical study reports
• Module 5 — clinical study reports

For ophthalmic products, Module 3 carries particular weight: sterility assurance, preservative efficacy, container-closure integrity, osmolality, pH and viscosity specifications all sit here.

Since January 2016, applications are filed through the SUGAM portal (cdscoonline.gov.in) — a single-window online system for applications, fee payment, query responses and licence downloads. Paper filing has been phased out.

Step 3: Clinical Data Requirements (and Waivers)

Under the NDCT Rules 2019, a genuinely new molecule requires local clinical trial data, approved by a registered Ethics Committee and permitted by CDSCO. Two provisions soften this for many ophthalmic products:

1. Rule 122A-style waivers (now embedded in the NDCT Rules): local clinical trial requirements can be waived for drugs already approved and well-established in specified countries, where CDSCO judges it in the public health interest.
2. The four-year rule: a drug ceases to be a "new drug" four years after its first approval in India. After that, other manufacturers can produce it under a state manufacturing licence without fresh central approval — though bioequivalence data may still be required where applicable.

This is why the Indian market fills with quality generic versions of molecules like moxifloxacin and travoprost within a few years of first approval.

Step 4: Review, SEC Opinion and Decision

CDSCO's review typically involves:

• Technical scrutiny of the dossier by CDSCO reviewers.
• Subject Expert Committee (SEC) evaluation for new molecules and FDCs — the SEC assesses therapeutic justification, safety margins and whether the combination is rational (a live issue for ophthalmic FDCs, many of which have been examined for rationality).
• Deficiency letters where data is incomplete — the applicant responds via SUGAM; failure to respond in time can mean rejection.
• Site inspection where warranted, checking GMP compliance, data integrity and batch consistency.

For approved applications, permissions flow through defined forms: Form 45 (licence to import a new drug) or Form 46 (licence to manufacture a new drug), with clinical trial permission issued in Form CT-06 under the 2019 rules.

Step 5: State Manufacturing and Sale Licences

Once a molecule is past the new-drug stage (or never was one), the path runs through the State Drugs Control Authority of the state where the factory sits:

• Application for a manufacturing licence in the prescribed form (Forms 24/25 series for non-biological drugs).
• Joint inspection by state and, in many cases, central inspectors against Schedule M (Good Manufacturing Practices) — revised in December 2023 to align with WHO GMP for sterile products, including explicit requirements for sterile ophthalmic preparations.
• Grant of licence, product-by-product permissions, and ongoing compliance: retention samples, batch records, pharmacovigilance reporting and periodic licence renewal.

Practical timelines vary considerably: a straightforward generic ophthalmic on a compliant site may clear in months; a new molecule or contested FDC can take several years through SEC review cycles.

Step 6: Post-Approval Obligations

Approval is not the end of the road. Manufacturers must maintain:

• Pharmacovigilance — adverse drug reaction reporting under the Pharmacovigilance Programme of India (PvPI), with periodic safety update reports where required.
• Change control — variations to formulation, site or process require regulatory notification or approval.
• Labelling compliance — Schedule-based labelling rules, including the red Schedule H/H1 prescription warnings on the carton where applicable.
• Quality alerts and recall readiness — CDSCO publishes quality alerts; manufacturers must have validated recall systems.

Common Pitfalls That Delay Approvals

Published analyses of CDSCO quality alerts and regulatory commentary point to recurring failure modes applicants should avoid:

• Weak stability packages. Ophthalmic submissions stumble when stability data doesn't cover the proposed shelf life under Zone IVb (hot, humid) conditions, or when the container-closure system studied differs from the marketed pack.
• FDC rationality gaps. Fixed-dose combinations face SEC scrutiny on therapeutic justification: does each component contribute, is the ratio defensible, does the combination reduce adherence burden? Combinations that fail the rationality test have been restricted or banned over the years — a live risk in the crowded antibiotic-steroid space.
• Incomplete preservative data. Preservative efficacy testing, preservative assay limits across shelf life, and justification of preservative concentration are frequent query triggers for multidose products.
• Slow query responses. Deficiency letters are normal; letting them lapse is not. Most timelines quoted for "CDSCO delays" include applicant-side response time.
• Site unpreparedness. Where inspection is triggered, data-integrity lapses (missing audit trails, backdated records) convert a routine review into a compliance crisis.

The Four-Year Rule and Its Market Consequences

The definition of a "new drug" — a substance approved in India for less than four years — has a deliberate market-shaping effect. During the window, the innovator or first licensees enjoy a protected position; after it, any manufacturer with a compliant site and a state licence can enter with a generic version. For ophthalmology, where most workhorse molecules (moxifloxacin, travoprost, nepafenac, olopatadine) are well past the window, this is why the market is a branded-generics battleground rather than a patent-protected one — and why quality and distribution, not exclusivity, decide share.

What Buyers Should Verify

When a distributor or hospital evaluates an ophthalmic supplier, the regulatory trail above translates into a concrete checklist:

1. Valid state manufacturing licence covering the specific products offered.
2. Product permissions for each formulation and strength.
3. For newer molecules or FDCs, evidence of CDSCO (DCGI) approval.
4. GMP/Schedule M compliance evidence — ideally WHO-GMP certification.
5. Stability data supporting the labelled shelf life, and batch-wise Certificates of Analysis.

A manufacturer that produces this documentation readily — as Oculentis Medical does for products like the Moxilux range and Tobalux-F — is one whose regulatory house is in order. Conversely, a supplier who promises to "share documents after the first order" is asking you to carry regulatory risk that belongs to them. In an era of risk-based CDSCO inspections and published quality alerts, the documentation pack is not bureaucracy; it is the product's legal identity.

Frequently Asked Questions

Does every eye drop need CDSCO (central) approval?

No. Central approval through CDSCO is required for new drugs, new fixed-dose combinations, clinical trials and imports. Once a molecule has been approved in India for four years, other manufacturers can produce it under a manufacturing licence issued by the State Drugs Control Authority, without a fresh central new-drug application.

What is Form 44 used for?

Form 44 is the application to CDSCO for permission to import, manufacture or conduct clinical trials of a new drug in India, supported by a CTD-format dossier. Successful Form 44 applications for import or manufacture result in licences in Form 45 or Form 46 respectively.

How long does eye drop approval take in India?

It depends entirely on the pathway. A new molecule going through SEC review and possible local data requirements can take several years. A generic version of a long-approved molecule, manufactured on a compliant site, may obtain its state licence in a matter of months. Queries and deficiency letters are the most common cause of delay.

What is the SUGAM portal?

SUGAM is CDSCO's online single-window platform (cdscoonline.gov.in), launched in January 2016, through which applications, fees, query responses and licence downloads are handled. It has replaced paper-based filing for most regulatory submissions.

Are imported eye drops regulated differently?

Imported products follow the same new-drug logic, plus an import registration route: the foreign manufacturing site is registered, Form 44 data is reviewed, and import licences (Form 45/Form 10 series) are issued. The foreign site must also meet GMP expectations, and CDSCO can inspect overseas facilities.

---

This article summarises published Indian drug regulatory requirements for general education. It is not legal or regulatory advice; consult CDSCO guidance and a qualified regulatory professional for specific filings.

Questions about the regulatory documentation behind our products? Contact the Oculentis team — we support distributors and institutional buyers with complete compliance dossiers.